JLPC(SH:600513) Shang Hai Zheng Quan Bao·2025-10-13 19:38Core Points - The resignation of independent director Hu Yiqiao due to personal reasons will not reduce the number of independent directors below the legal requirement, but it will affect the composition of the board's specialized committees [1][2] - The company held a half-year performance briefing on October 13, 2025, to discuss financial status and development strategies with investors [3][4] Summary by Sections Resignation of Independent Director - Hu Yiqiao has submitted her resignation as an independent director and from various committee roles due to personal reasons [1] - The resignation will take effect after the company adjusts its specialized committees, although she will continue to fulfill her duties until then [1][2] Half-Year Performance Briefing - The performance briefing was conducted online, featuring key executives including the chairman and general manager [3] - The company disclosed its R&D expenses for the first half of the last three years: 33.52 million in 2023, 67.58 million in 2024, and 68.42 million in 2025 [5] - The company is focusing on innovation-driven development, with significant R&D investments, including 277 million for 2024, representing 12.82% of revenue, and 145 million for the first half of 2025, accounting for 11.26% of revenue [5] - The company is actively pursuing new drug development in various therapeutic areas and has multiple products at different clinical trial stages [5]